Skip to main content

Table 1 Biodistribution of 111In-tilmanocept

From: Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept

Organs Non-blocked Blocked
Blood 0.18 ± 0.02 0.2 ± 0.1
Heart 2.2 ± 0.3 1.22 ± 0.05*
Stomach 3.4 ± 0.4 1.7 ± 0.3*
Lung 1.2 ± 0.2 1.1 ± 0.1
Salivary glands 4.4 ± 0.5 1.8 ± 0.2*
Liver 22.6 ± 2.7 14.7 ± 1.3*
Pancreas 3.4 ± 0.2 1.2 ± 0.1*
Spleen 10.4 ± 2.0 6.2 ± 0.3*
Small intestine 1.9 ± 0.8 1.6 ± 0.5
Large intestine 1.3 ± 0.2* 2.5 ± 0.2
Fat 1.02 ± 0.58 0.24 ± 0.03
Skin 1.3 ± 0.2 1.2 ± 0.3
Muscle 0.7 ± 0.2 0.50 ± 0.04
Bone 2.5 ± 0.5 2.2 ± 0.7
Kidney 23.2 ± 5.7* 55.7 ± 4.0
Carcass 14.2 ± 1.7* 22.2 ± 1.1
GI 3.8 ± 1.7 2.9 ± 0.2
Aortaa 0.005 ± 0.000 N/A
  1. Biodistribution of 111In-tilmanocept (1.5 pmol/g of body weight) in female C57BL/6 mice, 1 h p.i. Blocked group was co-injected with blocking dose (10 nmol) of non-labelled tilmanocept. Data are presented as the mean percentage of injected dose per gram of tissue (%ID/g ± SD) except in carcass, gastrointestinal tract (GI) and aortas (dissected only from non-blocked mice, n = 2) where the uptakes are presented as %ID per whole sample.
  2. N/A not applicable
  3. *Show significantly lower uptake (p < 0.05)
  4. aWhole aortas from the sinotubular junction to aortic bifurcation were collected